A consortium of Kvantify, Atom Computing, and Aarhus University has initiated the EarlyBIRDD project, funded with DKK 30 million from Innovation Fund Denmark, to harness quantum computing for accelerated drug discovery1. The primary objective is to enhance molecular simulations, specifically predicting drug-protein binding affinity, by co-developing quantum chemistry methods and algorithms. This collaboration aims to integrate these advancements into industry-ready software tools, potentially reducing pharmaceutical development timelines. By focusing on quantum computing methods and software development, the project seeks to overcome existing limitations in molecular simulations. The outcome of this initiative could significantly impact the pharmaceutical industry by streamlining the drug discovery process. This matters to practitioners as it underscores the potential of quantum computing to revolutionize complex fields like drug discovery, prompting informed readers to consider the broader implications of quantum technology on their industries.